Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

Allogeneic hematopoietic stem cell transplantation from unmanipulated haploidentical donor and unrelated cord blood for T-cell lymphoma: a retrospective study from the Société Francophone de Greffe de Moelle et de Therapie Cellulaire

Bone Marrow Transplantation volume 56, pages 2849–2856 (2021)Cite this article

Subjects

Abstract

After chemotherapy, fewer than 30% of patients with T-cell lymphoma (T-NHL) are long-term disease-free survivors. Thus, there is a growing interest in allogeneic stem cell transplantation (alloSCT) and its potential graft-versus-lymphoma effect (GVL) for patient with high-risk or recurrent T-NHL with the aim at providing durable disease control in T-NHL. We conducted this registry study to evaluate the outcome of recipients of alternative donor alloSCT for T-NHL. Patients transplanted with Haploidentical donor (Haplo, n = 41) or Umbilical Cord Blood (UCB, n = 54) were analyzed for overall survival (OS), non-relapse mortality (NRM), relapse, and acute/chronic graft-versus-host disease (aGVHD/cGVHD) incidence. At 2 years, OS and PFS were, respectively, of 59% and 53%, without significant difference between Haplo and UCB. In multivariate analysis, disease status at transplant was an independent risk factor for OS and PFS, and aGVHD III–IV was the main factor for OS and NRM. While no major impact of donor source on survival and mortality was noted, this study suggests that alternative donor transplantation appears feasible and offers benefits to patients with T-cell lymphoma.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Cumulative incidence of GVHD.
Fig. 2: Outcome after alloHSCT.

Similar content being viewed by others

References

  1. Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127:2375–90.

    Article  CAS  Google Scholar 

  2. Vose J, Armitage J, Weisenburger D, International T-Cell Lymphoma Project. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26:4124–30.

    Article  Google Scholar 

  3. Ellin F, Landström J, Jerkeman M, Relander T. Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry. Blood. 2014;124:1570–7.

    Article  CAS  Google Scholar 

  4. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. 2017. https://publications.iarc.fr/Book-And-Report-Series/Who-Classification-Of-Tumours/WHO-Classification-Of-Tumours-Of-Haematopoietic-And-Lymphoid-Tissues-2017.

  5. Perrone G, Giulia P, Corradini P. Autologous stem cell transplantation for T-cell lymphomas. Semin Hematol. 2014;51:59–66.

    Article  Google Scholar 

  6. Fossard G, Broussais F, Coelho I, Bailly S, Nicolas-Virelizier E, Toussaint E, et al. Role of up-front autologous stem-cell transplantation in peripheral T-cell lymphoma for patients in response after induction: an analysis of patients from LYSA centers. Ann Oncol. 2018;29:715–23.

    Article  CAS  Google Scholar 

  7. Schmitz N, Truemper L, Ziepert M, Bouabdallah K, Cartron G, Nickelsen M, et al. First-line therapy of T-cell lymphoma: Allogeneic or autologous transplantation for consolidation—final results of the AATT study. JCO. 2019;37:7503.

    Article  Google Scholar 

  8. d’Amore F, Gaulard P, Trümper L, Corradini P, Kim W-S, Specht L, et al. Peripheral T-cell lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26:v108–15.

    Article  Google Scholar 

  9. Kharfan-Dabaja MA, Kumar A, Ayala E, Hamadani M, Reimer P, Gisselbrecht C, et al. Clinical practice recommendations on indication and timing of hematopoietic cell transplantation in mature T cell and NK/T cell lymphomas: an international collaborative effort on behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transpl. 2017;23:1826–38.

    Article  Google Scholar 

  10. Schmitz N, de Leval L. How I manage peripheral T-cell lymphoma, not otherwise specified and angioimmunoblastic T-cell lymphoma: current practice and a glimpse into the future. Br J Haematol. 2017;176:851–66.

    Article  CAS  Google Scholar 

  11. Wilhelm M, Smetak M, Reimer P, Geissinger E, Ruediger T, Metzner B, et al. First-line therapy of peripheral T-cell lymphoma: extension and long-term follow-up of a study investigating the role of autologous stem cell transplantation. Blood Cancer J. 2016;6:e452.

    Article  CAS  Google Scholar 

  12. d’Amore F, Relander T, Lauritzsen GF, Jantunen E, Hagberg H, Anderson H, et al. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol. 2012;30:3093–9.

    Article  Google Scholar 

  13. Corradini P, Dodero A, Zallio F, Caracciolo D, Casini M, Bregni M, et al. Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin’s lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells. J Clin Oncol. 2004;22:2172–6.

    Article  Google Scholar 

  14. Hamadani M, Awan FT, Elder P, Lin TS, Porcu P, Blum KA, et al. Allogeneic hematopoietic stem cell transplantation for peripheral T cell lymphomas; evidence of graft-versus-T cell lymphoma effect. Biol Blood Marrow Transpl. 2008;14:480–3.

    Article  Google Scholar 

  15. Le Gouill S, Milpied N, Buzyn A, De Latour RP, Vernant J-P, Mohty M, et al. Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Société Francaise de Greffe de Moëlle et de Thérapie Cellulaire. J Clin Oncol. 2008;26:2264–71.

    Article  Google Scholar 

  16. Corradini P, Vitolo U, Rambaldi A, Miceli R, Patriarca F, Gallamini A, et al. Intensified chemo-immunotherapy with or without stem cell transplantation in newly diagnosed patients with peripheral T-cell lymphoma. Leukemia. 2014;28:1885–91.

    Article  CAS  Google Scholar 

  17. Friedrichs B, Stelljes M, Schmitz N. The role of allogeneic stem cell transplantation in T-cell lymphoma. Curr Opin Oncol. 2018;30:301–7.

    Article  Google Scholar 

  18. Bachanova V, Burns LJ, Wang T, Carreras J, Gale RP, Wiernik PH, et al. Alternative donors extend transplantation for patients with lymphoma who lack an HLA matched donor. Bone Marrow Transpl. 2015;50:197–203.

    Article  CAS  Google Scholar 

  19. Ghosh N, Karmali R, Rocha V, Ahn KW, DiGilio A, Hari PN, et al. Reduced-intensity transplantation for lymphomas using haploidentical related donors versus HLA-matched sibling donors: a center for international blood and marrow transplant research analysis. J Clin Oncol. 2016;34:3141–9.

    Article  CAS  Google Scholar 

  20. Kanate AS, Mussetti A, Kharfan-Dabaja MA, Ahn KW, DiGilio A, Beitinjaneh A, et al. Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors. Blood. 2016;127:938–47.

    Article  CAS  Google Scholar 

  21. Xiao X, Huang H, Chen J, Jiang Y, Zhang L, Xu Y, et al. Haploidentical hematopoietic stem cell transplantation with myeloablative conditioning regimen could serve as an optional salvage therapy for younger patients with refractory or relapsed aggressive non-Hodgkin lymphoma. Leuk Lymphoma. 2017;58:2957–61.

    Article  Google Scholar 

  22. Luznik L, O’Donnell PV, Symons HJ, Chen AR, Leffell MS, Zahurak M, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transpl. 2008;14:641–50.

    Article  CAS  Google Scholar 

  23. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. Consensus conference on acute GVHD grading. Bone Marrow Transpl. 1995;15:825–8.

    CAS  Google Scholar 

  24. Arora M, Klein JP, Weisdorf DJ, Hassebroek A, Flowers MED, Cutler CS, et al. Chronic GVHD risk score: a Center for International Blood and Marrow Transplant Research analysis. Blood. 2011;117:6714–20.

    Article  CAS  Google Scholar 

  25. Mamez A-C, Dupont A, Blaise D, Chevallier P, Forcade E, Ceballos P, et al. Allogeneic stem cell transplantation for peripheral T cell lymphomas: a retrospective study in 285 patients from the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC). J Hematol Oncol. 2020;13:56.

    Article  Google Scholar 

  26. Mehta-Shah N, Teja S, Tao Y, Cashen A, Beaven A, Alpdogan O, et al. Successful treatment of mature T-cell lymphoma with allogeneic stem cell transplantation: the largest multicenter retrospective analysis. Blood. 2017;130:4597.

    Article  Google Scholar 

  27. Delioukina M, Zain J, Palmer JM, Tsai N, Thomas S, Forman S. Reduced-intensity allogeneic hematopoietic cell transplantation using fludarabine–melphalan conditioning for treatment of mature T-cell lymphomas. Bone Marrow Transplant. 2012;47:65–72.

    Article  CAS  Google Scholar 

  28. Czajczynska A, Günther A, Repp R, Humpe A, Schub N, Raff T, et al. Allogeneic stem cell transplantation with BEAM and alemtuzumab conditioning immediately after remission induction has curative potential in advanced T-cell non-Hodgkin’s lymphoma. Biol Blood Marrow Transplant. 2013;19:1632–7.

    Article  CAS  Google Scholar 

  29. Kyriakou C, Canals C, Finke J, Kobbe G, Harousseau J-L, Kolb H-J, et al. Allogeneic stem cell transplantation is able to induce long-term remissions in angioimmunoblastic T-cell lymphoma: a retrospective study from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2009;27:3951–8.

    Article  Google Scholar 

  30. Dodero A, Spina F, Narni F, Patriarca F, Cavattoni I, Benedetti F, et al. Allogeneic transplantation following a reduced-intensity conditioning regimen in relapsed/refractory peripheral T-cell lymphomas: long-term remissions and response to donor lymphocyte infusions support the role of a graft-versus-lymphoma effect. Leukemia. 2012;26:520–6.

    Article  CAS  Google Scholar 

  31. Kanakry JA, Kasamon YL, Gocke CD, Tsai H-L, Davis-Sproul J, Ghosh N, et al. Outcomes of related donor HLA-identical or HLA-haploidentical allogeneic blood or marrow transplantation for peripheral T cell lymphoma. Biol Blood Marrow Transpl. 2013;19:602–6.

    Article  CAS  Google Scholar 

  32. Fuchs EJ, O’Donnell PV, Eapen M, Logan B, Antin JH, Dawson P, et al. Double unrelated umbilical cord blood vs HLA-haploidentical bone marrow transplantation: the BMT CTN 1101 trial. Blood. 2021;137:420–8.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institut de Cancérologie Lucien Neuwirth, Saint-Priest-en-Jarez, France

    Jerome Cornillon, Elisabeth Daguenet & Fabien Tinquaut

  2. CHU de Clermont-Ferrand, Clermont-Ferrand, France

    Olivier Tournilhac & Jacques-Olivier Bay

  3. Institut Paoli Calmettes, Marseille, France

    Didier Blaise

  4. Hopital La Pitie-Salpetriere, APHP, Paris, France

    Stephanie NGuyen

  5. Hopital Lyon Sud, Hospices Civils de Lyon, Pierre Bénite, France

    Helene Labussiere Wallet

  6. CHU de Nantes, Nantes, France

    Patrice Chevallier

  7. Hopital Saint-Antoine, APHP, Paris, France

    Rémy Dulery

  8. CHU de Bordeaux, Bordeaux, France

    Edouard Forcade

  9. CHRU de Lille, Lille, France

    Micha Srour

  10. American University of Beirut, Beirut, Lebanon

    Ali Bazarbachi

  11. CHU de Rouen, Rouen, France

    Nathalie Contentin

  12. CHU de Strasbourg, Strasbourg, France

    Bruno Lioure

  13. CHU de Grenoble, Grenoble, France

    Claude-Eric Bulabois

  14. Hopital Brabois, Nancy, France

    Marie-Therese Rubio

  15. Hopital Saint-Louis, Paris, France

    Marie Robin

Authors
  1. Jerome Cornillon
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Elisabeth Daguenet
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Olivier Tournilhac
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Didier Blaise
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Stephanie NGuyen
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Helene Labussiere Wallet
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Patrice Chevallier
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Rémy Dulery
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Edouard Forcade
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Micha Srour
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Ali Bazarbachi
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Nathalie Contentin
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Bruno Lioure
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Fabien Tinquaut
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Claude-Eric Bulabois
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Marie-Therese Rubio
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Marie Robin
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. Jacques-Olivier Bay
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

JC, ED, FT, and J-OB designed the research and/or analyzed the data. JC, ED, DB, SN, HLW, PC, RD, EF, MS, AB, NC, BL, C-EB, M-TR, MR, and J-OB collected the data. JC, ED, and FT performed the statistical analysis. JC and ED wrote the paper. All the authors approved the final manuscript.

Corresponding author

Correspondence to Jerome Cornillon.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cornillon, J., Daguenet, E., Tournilhac, O. et al. Allogeneic hematopoietic stem cell transplantation from unmanipulated haploidentical donor and unrelated cord blood for T-cell lymphoma: a retrospective study from the Société Francophone de Greffe de Moelle et de Therapie Cellulaire. Bone Marrow Transplant 56, 2849–2856 (2021). https://doi.org/10.1038/s41409-021-01426-3

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41409-021-01426-3

Search

Advanced search

Quick links